KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $734.3 million.

  • Recursion Pharmaceuticals' Non-Current Assets rose 171.64% to $685.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $685.4 million, marking a year-over-year increase of 171.64%. This contributed to the annual value of $734.3 million for FY2024, which is 240.66% up from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Non-Current Assets is $734.3 million, which was up 240.66% from $215.6 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Non-Current Assets ranged from a high of $734.3 million in FY2024 and a low of $32.1 million during FY2020.
  • Over the past 3 years, Recursion Pharmaceuticals' median Non-Current Assets value was $215.6 million (recorded in 2023), while the average stood at $360.5 million.
  • Data for Recursion Pharmaceuticals' Non-Current Assets shows a peak YoY spiked of 240.66% (in 2024) over the last 5 years.
  • Over the past 5 years, Recursion Pharmaceuticals' Non-Current Assets (Yearly) stood at $32.1 million in 2020, then spiked by 135.25% to $75.6 million in 2021, then soared by 73.85% to $131.5 million in 2022, then spiked by 63.96% to $215.6 million in 2023, then soared by 240.66% to $734.3 million in 2024.